[HTML][HTML] The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis
S Singh, S Boyd, WHK Schilling… - Journal of …, 2024 - academic.oup.com
Background Effective antiviral drugs accelerate viral clearance in acute COVID-19
infections; the relationship between accelerating viral clearance and reducing severe …
infections; the relationship between accelerating viral clearance and reducing severe …
[HTML][HTML] Incidence and co-infection with COVID-19 of dengue during the COVID-19 pandemic
YP Hung, CC Lee, YW Chen, JC Lee, CW Chiu… - Journal of the Formosan …, 2024 - Elsevier
The co-infection of dengue and COVID-19 has been regarded as a public health issue for
dengue-endemic countries during the COVID-19 pandemic. Travel restrictions might …
dengue-endemic countries during the COVID-19 pandemic. Travel restrictions might …
[HTML][HTML] A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy
In a pivotal trial (EPIC-HR), a 5-day course of oral ritonavir-boosted nirmatrelvir, given early
during symptomatic SARS-CoV-2 infection (within three days of symptoms onset) …
during symptomatic SARS-CoV-2 infection (within three days of symptoms onset) …
[HTML][HTML] Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis …
P Wongnak, WHK Schilling, P Jittamala… - The Lancet Infectious …, 2024 - thelancet.com
Background Effective antiviral drugs prevent hospitalisation and death from COVID-19.
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
Antiviral efficacy can be efficiently assessed in vivo by measuring rates of SARS-CoV-2 …
Estimates of Actual and Potential Lives Saved in the United States from the use of COVID-19 Convalescent Plasma
In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent
plasma (CCP) for the treatment of hospitalized patients. Over 500,000 patients were treated …
plasma (CCP) for the treatment of hospitalized patients. Over 500,000 patients were treated …
[HTML][HTML] A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral …
In a pivotal trial (EPIC-HR), a 5-day course of oral ritonavir-boosted nirmatrelvir, given early
during symptomatic SARS-CoV-2 infection (within three days of symptoms onset) …
during symptomatic SARS-CoV-2 infection (within three days of symptoms onset) …
Response to Drs de Grooth and Parienti
TO THE EDITOR—We appreciate very much the updated trial-level surrogacy analysis by
Drs de Grooth and Parienti and their insightful comments concerning individual-and trial …
Drs de Grooth and Parienti and their insightful comments concerning individual-and trial …